Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 62

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 62
---
quire
                                            the rights to a drug from a biopharmaceutical industry company or academia;

●use
                                            the proprietary bfLEAP™ AI/ML platform to determine a multi-factorial profile for a
                                            patient that would best respond to the drug;

●rapidly
                                            conduct a clinical trial to validate the drug’s use for the defined “high-responder”
                                            population; and

●divest
                                            and sell the rescued drug asset with the new information back to a large player in the pharma
                                            industry, following positive results of the clinical trial.

As
part of our strategy, we will continue evolving our intellectual property, analytical platform and technologies, build a large portfolio
of drug candidates, and implement a model that reduces risk and increases the frequency of cash flow from rescued drugs. This strategy
will include strategic partnerships, collaborations, and relationships along the entire drug development value chain, as well as acquisitions
of the rights to developing failed drugs and possibly the underlying companies.

To
date, we have not conducted clinical trials on any pharmaceutical drugs and our platform has not been used to identify a drug candidate
that has received regulatory approval for commercialization. However, we currently have a strategic relationship with a leading rare
disease non-profit organization for AI/ML analysis of late-stage clinical data. We have acquired the rights to a series of preclinical
and early clinical drug assets from universities and entered into a strategic collaboration with a world-renowned research institution
to create a HSV1 viral therapeutic platform to engineer immunotherapies for colorectal cancer. We have signed exclusive worldwide license
agreements with Johns Hopkins University for a cancer drug that targets glioblastoma (brain cancer), pancreatic cancer, and other cancers.
We have also signed an exclusive worldwide license with George Washington University for another cancer drug that targets hepatocellular
carcinoma (liver cancer), and other liver diseases.

Our
platform was originally developed by JHU-APL. JHU-APL uses the same technology for applications related to national defense. Over several
years, the software and algorithms have been used to identify relationships, patterns, and anomalies, and make predictions that otherwise
may not be found. These discoveries and insights provide an advantage when predicting a target of interest, regardless of industry or
sector. We have applied the technology to various clinical data sets and have identified novel relationships that may provide new intellectual
property, new drug targets, and other valuable information that may help with patient stratification for a clinical trial